Related Experiment Video
Updated: Aug 15, 2026

Mouse In Vivo Placental Targeted CRISPR Manipulation
Published on: April 14, 2023
Misoprostol administration in medical abortion. A comparison of three regimens
1Department of Family Practice, University of British Columbia, Vancouver, B.C., Canada. ewiebe@interchange.ubc.ca
Objective:
To determine the best regimen for using misoprostol after methotrexate in medical abortion with respect to outcome and side effects.
Study Design:
In a cohort study, we compared vaginal misoprostol in one cohort of 134 women who used 800 micrograms dry tablets with 99 women who used 600 micrograms wet and 197 women who used 800 micrograms wet. These cohorts were compared with respect to outcome and side effects.
Results:
The "dry" group had fewer completed abortions by day 8 (55.2% as compared to 69.7% and 71.1%, P = .008) but similar surgery rates. The dry group also had fewer side effects, especially fever and chills (4.5% as compared to 25.3% and 40.6%, P = .0001) and vomiting (8.2% as compared to 16.2% and 20.3%, P = .01).
Conclusion:
Of the three methods, the one consisting of 600 micrograms of wet misoprostol is the most effective for early completion of abortion and has the fewest side effects.
Related Concept Videos
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Intrauterine Drug Delivery Systems
Mitral Regurgitation III: Medical Management

